Working… Menu

Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00485719
Recruitment Status : Completed
First Posted : June 13, 2007
Last Update Posted : May 30, 2013
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine the safety and tolerability of XL765. XL765 is a new chemical entity that inhibits the kinases PI3K and mTOR. In preclinical studies, inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells, whereas inactivation of mTOR has been shown to inhibit the growth of tumor cells.

Condition or disease Intervention/treatment Phase
Cancer Drug: XL765 (SAR245409) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 83 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL765 Administered Orally Daily to Subjects With Solid Tumors
Study Start Date : June 2007
Actual Primary Completion Date : September 2012
Actual Study Completion Date : September 2012

Arm Intervention/treatment
Experimental: 1
Twice daily (bid) dosing
Drug: XL765 (SAR245409)
Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths administered orally

Experimental: 2
Once daily (qd) dosing
Drug: XL765 (SAR245409)
Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths administered orally

Primary Outcome Measures :
  1. Safety, tolerability, and maximum tolerated dose (MTD) of daily oral administration of XL765 in two treatment schedules [ Time Frame: Assessed at each visit/periodic visits ]

Secondary Outcome Measures :
  1. Plasma pharmacokinetics of daily oral administration of XL765 in two treatment schedules [ Time Frame: Assessed at periodic visits ]
  2. Pharmacodynamic effects of XL765 on tumor tissue when administered at the MTD in two treatment schedules [ Time Frame: Assessed during periodic vixits after MTD is determined ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subject has a histologically confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effective, and there are no therapies known to prolong survival.
  • The subject has disease that is assessable by tumor marker, physical, or radiologic means.
  • The subject is at least 18 years old.
  • The subject's weight is at lease 40 kg.
  • The subject has an Eastern Cooperative Oncology Group performance status of 0 - 2.
  • The subject has adequate organ and bone marrow function.
  • The subject has fasting plasma glucose < 120 mg/dL at screening.
  • for subjects who are to be enrolled into the Expanded MTD Cohort and Lower-Dose Tumor Genetic Alteration Subjects:

    1. tumor tissue amenable to serial biopsy;
    2. additional informed consent
  • The subject is capable of understanding the protocol and has signed the informed consent.
  • Sexually active subjects (male and female) must use medically acceptable methods of contraception during the course of the study.
  • Female subjects of childbearing potential must have a negative serum pregnancy test at screening.
  • If the subject has received more than 3 prior regimens of cytotoxic chemotherapy, more than 2 biologic regimens, or more than 3000 cGy to >25% of his or her bone marrow, the sponsor must determine subject suitability before enrollment.
  • The subject has had no other diagnosis of malignancy (unless non-melanoma skin cancer, in situ carcinoma of the cervix, or a malignancy diagnosed ≥ 2 years ago, and has had no evidence of disease for 2 years prior to screening for this study.)

Exclusion Criteria:

  • The subject has received anticancer treatment (chemotherapy, radiotherapy, cytokines, or hormones) within 30 days (6 weeks for nitrosoureas, mitomycin C, or bicalutamide) before the first dose of XL765.
  • The subject has received radiation to > 25% of his or her bone marrow.
  • The subject has not recovered from adverse events, except Grade 2 alopecia, due to other investigational or other agents administered prior to study enrollment.
  • The subject has received another investigational agent within 30 days or the first dose of XL765 or a small-molecule kinase inhibitor within 14 days or 5 half-lives.
  • The subject is known to have diabetes
  • The subject has uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
  • The subject has psychiatric illness/social situation that would limit compliance with study requirements.
  • The subject is pregnant or breast feeding.
  • The subject is known to be positive for HIV.
  • The subject has a known allergy or hypersensitivity to components of the XL765 formulation.
  • The subject has a baseline corrected QT interval > 450 ms.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00485719

Layout table for location information
United States, Michigan
Investigational Site Number 1302
Detroit, Michigan, United States, 48201
United States, Nebraska
Investigational Site Number 1435
Omaha, Nebraska, United States, 68198
United States, Texas
Investigational Site Number 1402
San Antonio, Texas, United States, 78229
Investigational Site Number 3411
Barcelona, Spain, 08035
Sponsors and Collaborators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Sanofi Identifier: NCT00485719    
Other Study ID Numbers: TED11440
2007-002437-36 ( EudraCT Number )
XL765-001 ( Other Identifier: (other study code) )
First Posted: June 13, 2007    Key Record Dates
Last Update Posted: May 30, 2013
Last Verified: May 2013
Keywords provided by Sanofi:
Solid Tumors